Iovance hikes 2026 revenue guidance
Iovance raised full-year 2026 revenue expectations to $410-$420 million due to strong U.S. demand for Amtagvi and Proleukin, marking a notable increase over the previous forecast.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed